| Execution period | Vesting over 3 years from the date of grant; exercisable within 1 year of vesting |
|---|
NSE filing, NSE: JUBLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹934.85
- Market cap
- ₹14,890 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 56.6×Sector 48.6×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Results Update
Q2 revenue rose 21% to Rs 2,370 Cr, but EBITDA fell 27% and PAT dropped to Rs 31 Cr. SPECT supply gaps and remediation costs compressed margins.
Jubilant Pharmova Q2 FY27 Results: Net Profit ₹31 Cr, Down 74.1% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,370 Cr (+20.5% YoY) and net profit of ₹31 Cr (-74.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹31 Cr · -74.1% YoY
Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
- Value
- ₹800.0 Cr
- Execution
- 3 years (maturity 05 November 2028)
Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Other employee stock options announcements
All →Renaissance Global Employee Stock Options
Renaissance Global allotted 10,000 equity shares to an employee on exercise of ESOPs at Rs 110 each. Paid-up capital rises to Rs 21.49 Crore.
Lodha Developers Employee Stock Options
Lodha Developers allotted 41,235 equity shares of Rs.10 each on November 18, 2026, under its ESOP Scheme 2021-II. No cash consideration or issue price is stated in the filing.
Orkla India Employee Stock Options
Orkla India allotted 10,757 equity shares to employees on exercise of options under MSOP 2025. Paid-up capital rises to Rs. 13,70,40,258 following the allotment.
HDFC Asset Management Company Employee Stock Options
HDFC AMC allotted 164,233 equity shares on exercise of employee stock options under its 2020 and 2025 schemes. Paid-up capital rises to Rs.2,14,62,78,055 across 42,92,55,611 shares.
Bajaj Healthcare Employee Stock Options
Bajaj Healthcare allotted 26,710 equity shares on ESOP exercise at ₹5 per option under its 2024 scheme. Money realised is about ₹1.34 lakh, and the paid-up capital rises to ₹16.85 Crore.
- Value
- ₹0.01 Cr
ideaForge Technology Employee Stock Options
ideaForge allotted 3,80,574 equity shares at Rs 10 each on exercise of ESOPs under its 2018 scheme. Paid-up capital rises to Rs 50.11 crore.